DCT

2:26-cv-04950

Pharmacosmos Holding As v. DR Reddy's Laboratories Ltd

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 2:26-cv-04950, D.N.J., 05/01/2026
  • Venue Allegations: Venue is alleged to be proper in the District of New Jersey because Defendant Dr. Reddy's Laboratories, Inc. is a New Jersey corporation with its principal place of business in the state. Venue over the foreign parent, Dr. Reddy's Laboratories, Ltd., is asserted on the basis that it may be sued in any judicial district.
  • Core Dispute: Plaintiff alleges that Defendant's Abbreviated New Drug Application (ANDA) to market a generic version of the intravenous iron-deficiency drug Injectafer will induce infringement of patents covering methods for treating iron deficiency while mitigating the side effect of hypophosphatemia.
  • Technical Context: The lawsuit concerns intravenous iron carbohydrate complexes, specifically ferric carboxymaltose, used for treating iron deficiency anemia in patients who cannot tolerate or do not respond to oral iron.
  • Key Procedural History: This is a patent infringement action filed under the Hatch-Waxman Act, triggered by Defendants' submission of ANDA No. 218848. The complaint notes that prior to the issuance of the asserted patents, the FDA label for the reference drug, Injectafer, was updated multiple times (in February 2020, May 2023, and January 2025) to include stronger warnings and monitoring protocols related to hypophosphatemia, based on new clinical findings. Plaintiff also notes it sent a notice letter to Defendants regarding the alleged infringement prior to filing suit.

Case Timeline

Date Event
2018-10-29 Earliest Priority Date for '934 and '486 Patents
2020-02-01 Injectafer label revised to add hypophosphatemia warnings
2023-05-01 Injectafer label revised with further warnings
2023-06-20 DRL reportedly obtains approval to market generic in India
2024-04-24 DRL sends Paragraph IV Certification for ANDA No. 218848
2025-01-03 Injectafer label most recently revised
2025-07-14 Prior litigation involving DRL settled
2025-09-22 Pharmacosmos files suit against Injectafer's NDA Holder
2025-05-13 U.S. Patent No. 12,295,934 Issues
2025-05-20 U.S. Patent No. 12,303,486 Issues
2026-03-11 Pharmacosmos sends notice letter to DRL
2026-03-20 DRL receives notice letter from Pharmacosmos
2026-05-01 Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 12,295,934 - "Treating Iron Deficiency with Ferric Carboxymaltose" (issued May 13, 2025)

The Invention Explained

  • Problem Addressed: The patent addresses the problem of hypophosphatemia (abnormally low serum phosphate) caused by the administration of ferric carboxymaltose (FCM) for iron deficiency Compl. ¶28 Prior to the invention, this side effect was considered transient and clinically irrelevant '934 Patent, col. 2:26-47 Compl. ¶30 The inventors discovered that repeated dosing of FCM leads to an "auto-synergistic" and unexpectedly large increase in the hormone iFGF23, which exacerbates hypophosphatemia and can lead to clinical consequences like reduced muscle function and increased bone turnover '934 Patent, col. 3:19-26 Compl. ¶¶31-32
  • The Patented Solution: The patent claims methods to reduce the severity of these side effects by instituting a specific protocol for repeated FCM treatments Compl. ¶39 The core of the solution is to require, prior to administering a further dose of FCM, that a healthcare provider first measure the patient's serum phosphate levels and, if low, treat the hypophosphatemia before proceeding with the next iron dose '934 Patent, claim 1 This protocol is designed to interrupt the "auto-synergistic" effect of repeat dosing on iFGF23 levels, which was a previously unknown phenomenon revealed in the "Phosphare trials" discussed in the patent '934 Patent, col. 3:10-26 Compl. ¶31 The complaint highlights patent figures showing clinical trial data that demonstrates the significant drop in phosphate levels and increase in iFGF23 after FCM administration compared to another iron formulation '934 Patent, Figs. 3, 6 Compl. ¶31
  • Technical Importance: This invention provided a method to safely administer repeat, high-dose courses of an effective intravenous iron therapy by managing a newly understood and clinically significant side effect Compl. ¶32

Key Claims at a Glance

  • The complaint asserts claims 1-60, focusing on independent claims 1 and 31 Compl. ¶55
  • Independent Claim 1 recites a method of reducing the severity of side effects, comprising the steps of:
    • administering a dose of ferric carboxymaltose to said subject;
    • determining that said subject needs a further dose of ferric carboxymaltose;
    • prior to administering the further dose of ferric carboxymaltose, measuring said subject's serum phosphate levels, and if said subject has hypophosphatemia, treating the hypophosphatemia as medically indicated prior to administering the further dose of ferric carboxymaltose; and
    • administering the further dose of ferric carboxymaltose to said subject.
  • Independent Claim 31 recites a similar method with a different sequence of steps:
    • administering a dose of ferric carboxymaltose to said subject;
    • determining that said subject needs a further dose of ferric carboxymaltose;
    • prior to administering the further dose of ferric carboxymaltose, first treating said subject with a medically indicated treatment for hypophosphatemia, then measuring said subject's serum phosphate levels; and
    • administering the further dose of ferric carboxymaltose to said subject.

U.S. Patent No. 12,303,486 - "Treating Iron Deficiency with Ferric Carboxymaltose" (issued May 20, 2025)

The Invention Explained

  • Problem Addressed: The '486 Patent, which shares a specification with the '934 patent, also addresses the problem of hypophosphatemia resulting from FCM administration Compl. ¶44 It specifically focuses on the risk of symptomatic hypophosphatemia, which the inventors found to be more frequent and clinically significant than previously understood '486 Patent, col. 2:26-47 Compl. ¶46
  • The Patented Solution: The solution is a therapeutic method nearly identical to that of the '934 patent, involving monitoring serum phosphate and treating hypophosphatemia before administering repeat doses of FCM '486 Patent, claim 1 Compl. ¶45 The method is intended to "reduce the risk of symptomatic hypophosphatemia" by managing the underlying biochemical mechanism involving the hormone iFGF23 '486 Patent, claim 1 Compl. ¶45
  • Technical Importance: This invention provided a specific protocol to mitigate the risk of clinically significant, symptomatic side effects from repeat courses of FCM treatment Compl. ¶46

Key Claims at a Glance

  • The complaint asserts claims 1-29, focusing on independent claim 1 Compl. ¶90
  • Independent Claim 1 recites a method of reducing the risk of symptomatic hypophosphatemia, comprising the steps of:
    • administering a dose of ferric carboxymaltose to said subject;
    • determining that said subject needs a further dose of ferric carboxymaltose;
    • prior to administering the further dose of ferric carboxymaltose, measuring said subject's serum phosphate levels, and if said subject has hypophosphatemia, treating the hypophosphatemia as medically indicated prior to administering the further dose of ferric carboxymaltose; and
    • administering the further dose of ferric carboxymaltose to said subject.

III. The Accused Instrumentality

Product Identification

  • The accused instrumentality is Defendants' proposed generic ferric carboxymaltose injection, which is the subject of ANDA No. 218848 ("DRL's ANDA Product") Compl. ¶1

Functionality and Market Context

  • The complaint alleges that DRL's ANDA Product is a generic version of the brand-name drug Injectafer and will have the same active ingredient, ferric carboxymaltose Compl. ¶¶23, 62 The core of the infringement allegation is that, pursuant to FDA regulations, the prescribing information ("DRL's Label") for the generic product must be materially the same as the current label for Injectafer Compl. ¶¶50; Compl. ¶57 The complaint alleges that these label instructions will direct healthcare providers to administer the product in a manner that practices the steps of the asserted patent claims, such as by directing repeat courses of treatment and instructing providers to monitor and treat hypophosphatemia Compl. ¶¶60-61 The complaint cites a chart from the '934 patent's Figure 3, which depicts clinical data showing a significantly higher incidence of hypophosphatemia in patients treated with FCM versus another iron therapy, illustrating the problem the patented method purports to solve Compl. ¶31

IV. Analysis of Infringement Allegations

'934 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method of reducing severity of side effects associated with hypophosphatemia in connection with repeated treatment of iron deficiency with ferric carboxymaltose to a subject in need thereof, said method comprising, The complaint alleges DRL's Label will instruct healthcare providers on how to reduce patients' side effects by including warnings and directing monitoring and treatment of hypophosphatemia in connection with repeated treatment. ¶61 col. 12:35-43
administering a dose of ferric carboxymaltose to said subject; DRL's ANDA Product contains ferric carboxymaltose, and its label will instruct physicians on its administration, such as a 750 mg dose. ¶62 col. 2:10-19
determining that said subject needs a further dose of ferric carboxymaltose; DRL's Label will allegedly instruct that treatment "may be repeated if IDA or iron deficiency in heart failure reoccurs," leading physicians to determine the need for a further dose. ¶63 col. 17:3-8
prior to administering the further dose of ferric carboxymaltose, measuring said subject's serum phosphate levels, and if said subject has hypophosphatemia, treating the hypophosphatemia as medically indicated prior to administering the further dose of ferric carboxymaltose; and DRL's Label will allegedly instruct providers to "[m]onitor serum phosphate levels" and "[t]reat hypophosphatemia as medically indicated" prior to a repeat course of treatment. ¶¶64-65 col. 17:9-17
administering the further dose of ferric carboxymaltose to said subject. DRL's Label will allegedly instruct physicians on administering a "repeat course of treatment" with ferric carboxymaltose. ¶66 col. 17:15-17
  • Identified Points of Contention:
    • Scope Questions: The dispute may center on whether the warnings and instructions in the accused product's label rise to the level of active inducement required by 35 U.S.C. § 271(b). A question for the court will be whether providing information about risks and recommending monitoring is equivalent to directing practitioners to perform the specific, ordered steps of the claimed method.
    • Technical Questions: A key question will be the sequence of the claimed steps versus the instructions on the label. Claim 1 requires a "measure, then treat if needed" sequence, while claim 31 requires a "treat, then measure" sequence. The analysis will question whether the accused label instructs one specific sequence over the other, or if it provides discretionary guidance that may not map directly onto either claimed method.

'486 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method of reducing risk of symptomatic hypophosphatemia associated with repeated treatment of iron deficiency with ferric carboxymaltose in a subject in need thereof, said method comprising, The complaint alleges DRL's Label will instruct providers on reducing the risk of symptomatic hypophosphatemia through warnings and directions for monitoring and treatment. ¶96 col. 12:35-43
administering a dose of ferric carboxymaltose to said subject; DRL's ANDA Product is ferric carboxymaltose, and its label will instruct physicians on its administration. ¶97 col. 2:10-19
determining that said subject needs a further dose of ferric carboxymaltose; DRL's Label will allegedly instruct that treatment may be repeated if iron deficiency reoccurs, leading physicians to determine the need for a further dose. ¶98 col. 17:3-8
prior to administering the further dose of ferric carboxymaltose, measuring said subject's serum phosphate levels, and if said subject has hypophosphatemia, treating the hypophosphatemia as medically indicated prior to administering the further dose of ferric carboxymaltose; and DRL's Label will allegedly instruct providers to "[m]onitor serum phosphate levels" and to "[t]reat hypophosphatemia as medically indicated" before a repeat course. ¶¶99-100 col. 17:9-17
administering the further dose of ferric carboxymaltose to said subject. DRL's Label will allegedly instruct physicians on administering a "repeat course of treatment." ¶101 col. 17:15-17
  • Identified Points of Contention:
    • Scope Questions: As with the '934 patent, a central issue will be whether the label instructions constitute inducement. Additionally, the construction of "reducing risk of symptomatic hypophosphatemia" will be critical. The court will need to determine what actions satisfy this "reducing risk" step and whether the label's warnings and monitoring guidelines meet that standard.
    • Technical Questions: The factual question remains whether healthcare providers, following the DRL Label, will necessarily perform all steps of the claim in the recited order. The defense may argue that the label provides discretionary guidance rather than a mandatory, infringing protocol.

V. Key Claim Terms for Construction

'934 Patent and '486 Patent

  • The Term: "treating the hypophosphatemia as medically indicated"

  • Context and Importance: This term appears in the core monitoring-and-treatment step of the independent claims of both asserted patents Compl. ¶¶59, 94 Its construction is critical because it involves physician discretion. Practitioners may focus on this term because the extent of discretion it affords could be central to the inducement analysis; if the label's instruction to "treat as medically indicated" is not a specific direction to perform an infringing act, it could weaken the inducement claim.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The specification does not appear to narrowly define what constitutes a "medically indicated" treatment, instead referring to standard medical care. This could support an interpretation that any professional medical response to diagnosed hypophosphatemia meets the limitation.
    • Evidence for a Narrower Interpretation: The patents link hypophosphatemia to specific downstream effects like reduced muscle function and bone turnover '934 Patent, col. 3:23-25 A party could argue that "medically indicated" treatment must be a treatment aimed at preventing these specific, inventor-identified consequences, rather than any general treatment for low phosphate.

  • The Term: "reducing severity of side effects" ('934 patent) / "reducing risk of symptomatic hypophosphatemia" ('486 patent)

  • Context and Importance: These phrases form the preambles of the primary independent claims and define the purpose of the method Compl. ¶¶59, 94 Whether these preambles are interpreted as limiting the scope of the claims will be a key issue. Practitioners may focus on this term because if the preamble is found to be limiting, the plaintiff would need to prove not only that the steps were performed, but also that they were performed with the specific purpose of reducing the severity/risk of hypophosphatemia.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation (Non-Limiting): The body of the claims recites a complete method with a series of concrete, physical steps (administering, measuring, treating). A party may argue that this structure renders the preamble a mere statement of intended purpose, which does not add limitations to the claim.
    • Evidence for a Narrower Interpretation (Limiting): The specification heavily emphasizes the inventors' discovery of the severity and risks of FCM-induced hypophosphatemia as the central problem solved '934 Patent, col. 2:48-col. 3:26 A party may argue that this context makes the preamble essential for understanding the invention and distinguishes it from the prior art, thereby rendering it a necessary limitation.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges induced infringement under 35 U.S.C. § 271(b) Compl. ¶¶55, 90 The theory is that Defendants, by seeking approval for and marketing their ANDA Product with a label that is materially the same as the Injectafer label, will actively and knowingly encourage and instruct healthcare professionals to perform the patented methods Compl. ¶¶53, 58, 81 The specific instructions on the label regarding repeat dosing and management of hypophosphatemia are the alleged basis for inducement Compl. ¶¶60-66
  • Willful Infringement: The complaint alleges that Defendants have had knowledge of the asserted patents at least since March 20, 2026, when they received a notice letter from Pharmacosmos Compl. ¶¶56, 79, 91, 104 The complaint also alleges Defendants "knew or should have known" of the infringement based on Pharmacosmos's public lawsuits against other parties concerning the same patents and technology, dating back to September 22, 2025 Compl. ¶¶80, 105

VII. Analyst's Conclusion: Key Questions for the Case

  • A core issue will be one of inducement: do the instructions and warnings on the accused generic drug label, which are expected to mirror those of the brand-name drug, constitute active encouragement for healthcare providers to perform the specific, ordered steps of the patented methods, or do they merely provide discretionary guidance that falls short of the legal standard for inducement?
  • A second key issue will be one of claim construction: can the preambles "reducing severity of side effects" and "reducing risk of symptomatic hypophosphatemia" be established as affirmative limitations on the claims, and what level of evidence is required to meet them? The interpretation of "treating... as medically indicated" will also be central, as it will define the degree of discretion afforded to physicians and its impact on the inducement analysis.
  • An evidentiary question will focus on the sequence of actions: does the accused label direct a specific sequence of "measure-then-treat" (as in '934 Claim 1) versus "treat-then-measure" (as in '934 Claim 31), and will the plaintiff be able to prove that practitioners will follow one of these specific infringing sequences, as opposed to a non-infringing or discretionary alternative?
Loading Complaint